Belpointe Asset Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Belpointe Asset Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.08M	Sell	9,860 -369	-4%	-$41.1K	0.03%	500
2026 Q2	$1.12M	Buy	10,229 +2,175	+27%	+$225K	0.04%	458
2026 Q1	$837K	Sell	8,054 -39	-0.5%	-$4.16K	0.03%	522
2025 Q4	$835K	Sell	8,093 -20	-0.2%	-$1.95K	0.03%	498
2025 Q3	$733K	Buy	8,113 +2,409	+42%	+$211K	0.03%	504
2025 Q2	$502K	Sell	5,704 -93	-2%	-$8.06K	0.02%	574
2025 Q1	$528K	Buy	+5,797	New	+$522K	0.03%	550
2023 Q2	–	Sell	-120	Closed	-$9.32K	–	2614
2023 Q1	$9.32K	Sell	120 -167	-58%	-$12.9K	﹤0.01%	2755
2022 Q4	$22.3K	Buy	+287	New	+$21.2K	﹤0.01%	2106

Other funds holding PPH

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $64.4B AUM 36.06% 1-Year Est. Return

J. Safra Asset Management New York $2.3B AUM 21.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.59B AUM 27.25% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Adamsbrown Wealth Consultants Wichita, Kansas $548M AUM 16.52% 1-Year Est. Return

Miller Investment Management West Conshohocken, Pennsylvania $1.13B AUM 13.3% 1-Year Est. Return

Belpointe Asset Management's PPH Position: Q3 2026 in Review

Belpointe Asset Management reduced its VanEck Pharmaceutical ETF (PPH) stake by 3.6% in Q3 2026, selling an estimated $41.1K and leaving 9,860 shares worth $1.08M. The position accounts for 0.03% of the portfolio, ranked #500.

Belpointe Asset Management first reported a position in PPH in Q4 2022 and has held it in 9 quarters since. The position peaked at $1.12M in Q2 2026. 124 funds tracked by Wall St. Rank hold PPH as of Q3 2026.

Belpointe Asset Management held 9,860 shares of VanEck Pharmaceutical ETF worth $1.08M as of Q3 2026.
Belpointe Asset Management sold 369 VanEck Pharmaceutical ETF shares in Q3 2026, an estimated $41.1K.
VanEck Pharmaceutical ETF made up 0.03% of Belpointe Asset Management's portfolio in Q3 2026, its #500 holding.
Belpointe Asset Management first reported a position in VanEck Pharmaceutical ETF in Q4 2022 and has held it in 9 quarters since.
Belpointe Asset Management's VanEck Pharmaceutical ETF position peaked at $1.12M in Q2 2026.
124 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2026.

Based on Belpointe Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.